Business Wire

MAXON Adds New Dimension to Design with Cineware for Adobe Illustrator CC

Del

MAXON, the leading developer of the professional 3D modeling, animation, painting and rendering solution Cinema 4D, today announced the release of Cineware for Illustrator. This new plugin allows artists and designers to add and edit 3D objects directly within Adobe Illustrator CC, the industry-standard vector graphics application included in the Adobe Creative Cloud.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171010005917/en/

Cineware for Adobe Illustrator CC (Graphic: Business Wire)

Cineware for Adobe Illustrator CC (Graphic: Business Wire)

Cineware for Illustrator uses the same powerful 3D engine as Cinema 4D, MAXON’s industry-leading, intuitive, professional 3D application. Users can import any C4D file, and tweak the view, lighting and textures to integrate 3D elements with 2D designs or use 3D elements as templates when creating vector artwork in Illustrator CC. This enables designers to visualize product labels, incorporate rich 3D content into Illustrator compositions, or even arrange 3D elements as guides for form and perspective when creating vector artwork.

MAXON has partnered with TurboSquid, the leading online source for 3D models, to provide Cineware for Illustrator users a “jump start” into the third dimension with a collection of ready-to-use 3D models, including common product packaging and other 3D objects. Users of Cinema 4D can create and share their own custom 3D content for use in Illustrator CC.

Motion designers have enjoyed similar integration of Cinema 4D technology within Adobe After Effects CC since the introduction of the Cineware bridge in 2013. Cineware for Illustrator offers designers the ability to adjust object visibility, textures and lighting all from within Adobe Illustrator.

“Cinema 4D has long offered a fantastic, easy-to-learn toolset for product visualization and graphic design,” says Harald Egel, managing partner at MAXON Computer GmbH. “With Cineware for Illustrator we’re making both the Cinema 4D toolset and 3D in general more accessible to designers, and plan to develop this workflow even further in the future.”

Cineware for Illustrator Feature Highlights

  • 3D Objects: Rotate, position and show/hide individual 3D objects from any Cinema 4D scene, all within Illustrator CC.
  • Materials: Adjust the color, reflection, luminance, transparency, and bump directly within Illustrator CC. Users can even apply vector artwork to the surface of 3D models.
  • Cameras: Switch between pre-set cameras or use simple navigation tools to choose preferred viewing angle.
  • Lights: Enable or disable lights, and change their color to set a mood and emphasize shapes.
  • Integrate: Workflow allows easy removal of the background by choosing the automatically created alpha map so 3D elements can be integrated into existing vector artwork.

Availability

Cineware for Illustrator is available at no cost for macOS and Windows 10 on the MAXON Website.

Cineware for Illustrator CC at Adobe MAX and NAB East

MAXON Cineware for Illustrator will debut in the MAXON booth in the Community Pavilion at Adobe MAX (October 18-20, 2017 in Las Vegas) and NAB Show NY, Booth N264 (October 18-19, 2017 in New York).

Cinema 4D Upgrade Path

For Illustrator CC users that desire a rich, full-features 3D content creation experience, MAXON offers an attractive upgrade path to Cinema 4D.

Video footage about Cineware for Illustrator

Promotion-Video

Workflow-Video #1

Workflow-Video #2

About MAXON

Headquartered in Friedrichsdorf, Germany, MAXON Computer is a developer of professional 3D modeling, painting, animation and rendering solutions. Its award-winning Cinema 4D and BodyPaint 3D software products have been used extensively to help create everything from stunning visual effects in top feature films, TV shows and commercials, cutting-edge game cinematics for AAA games, as well for medical illustration, architectural and industrial design applications. MAXON has offices in Germany, USA, United Kingdom, Canada, France, Japan and Singapore. MAXON products are available directly from the web site and its worldwide distribution channel. MAXON is part of the Nemetschek Group.

Additional information on MAXON can be obtained as follows

Website

Cineversity

Facebook

Twitter

YouTube

LinkedIn

Google+

Instagram

All trademarks contained herein are the property of their respective owners.

Contact information

Media Contact
MAXON
US Internal:
press_us@maxon.net
or
US Media Contact:
Vicky Gray-Clark
Ambient Public Relations
408-243-8880
vicky@ambientpr.com
or
UK:
Liam Stacy
press_uk@maxon.net
or
Japan:
Toshihide Miyata
press_jp@maxon.net
or
France:
Eric Godey
press_fr@maxon.net
or
Singapore/ASEAN:
Vincent Ong
press_sg@maxon.net
or
Germany and all other countries:
Jessica Wege
press_de@maxon.net

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an